.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,958,732

« Back to Dashboard

Details for Patent: 5,958,732

Title: Platelet aggregation inhibitors
Abstract:An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K* -(G/Sar)-D wherein K* is a modified lysyl residue of the formula wherein each R.sup.1 is independently H, alkyl(1-6C) or at most one R.sup.1 is R.sup.2 --C.dbd.NR.sup.3 wherein R.sup.2 is H, alkyl(1-6C) or is NR.sup.4.sub.2 in which each R.sup.4 is independently H or alkyl(1-6C) and R.sup.3 is H, alkyl(1-6C), phenyl or benzyl, or R.sup.2 --C.dbd.NR.sup.3 is a radical selected from the group consisting of: ##STR1## where m is an integer of 2-3, and each R.sup.5 is independently H or alkyl(1-6C); and wherein one or two (CH.sub.2) may be replaced by O or S provided said O or S is not adjacent to another heteroatom are prepared and shown to specifically inhibit the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa.
Inventor(s): Scarborough; Robert M. (Belmont, CA), Wolf; David Lawrence (Palo Alto, CA), Charo; Israel F. (Lafayette, CA)
Assignee: COR Therapeutics, Inc. (South San Francisco, CA)
Filing Date:Jun 07, 1995
Application Number:08/474,249
Claims:1. A DNA in isolated and purified form which encodes a PAI comprising naturally occurring protein amino acids, wherein said PAI:

comprises a KGD or RGD sequence,

is active by a method for determining the presence of platelet aggregation inhibitor activity, which method comprises contacting said platelet aggregation inhibitor with purified platelet GP IIb-Ha in the presence of a solution of fibrinogen or von Willebrand Factor under conditions wherein fibrinogen or von Willebrand Factor binds to said GP IIb-IIIa and detecting the decrease in the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa in comparison to the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa in a control which does not contain said platelet aggregation inhibitor, and

is a modified and/or truncated form of a PAI which is obtainable from a snake venom other than echistatin, trigramin, flavoviridin, elegantin, albolabrin, bitistatin, batroxostatin, halysin, applaggin, or derived from Agkistrodon rhodostoma, wherein said modified form differs from the native sequence by 1 to 10 conservative substitutions at other than the KGD or RGD sequence.

2. A recombinant expression system capable, when transformed into compatible host, of expressing the DNA of claim 1.

3. A recombinant host transformed with the expression system of claim 2.

4. A method to produce PAI which method comprises:

culturing the host of claim 3 under conditions effective to express the PAI-encoding DNA to produce PAI; and recovering the PAI from the culture.

5. A DNA in isolated and purified form which encodes a platelet aggregation inhibitor (PAI) comprising naturally occurring protein amino acids, wherein said PAI:

comprises a KGD or RGD sequence,

is active by a method for determining the presence of platelet aggregation inhibitor activity, which method comprises contacting said platelet aggregation inhibitor with purified platelet GP IIb-IIIa in the presence of a solution of fibrinogen or von Willebrand Factor under conditions wherein fibrinogen or von Willebrand Factor binds to said GP IIb-IIIa and detecting the decrease in the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa in comparison to the binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa in a control which does not contain said platelet aggregation inhibitor, and

is a modified and/or truncated form of a PAI which is obtainable from a snake venom with the proviso that said venom is not from Echis carinatus, Trimeresurus gramineus, T. flavoviridis, T. Elegans, T. albolabris, Bitis arietans, Bothrops atrox, Agkistrodon halys, Agkistrodon p. piscivorus, or Agkistrodon rhodostoma, wherein said modified form differs from the native sequence by 1 to 10 conservative substitutions at other than the KGD or RGD sequence.

6. A recombinant expression system capable, when transformed into compatible host, of expressing the DNA of claim 5.

7. A recombinant host transformed with the expression system of claim 6.

8. A method to produce PAI which method comprises:

culturing the host of claim 7 under conditions effective to express the PAI-encoding DNA to produce PAI; and recovering the PAI from the culture.

9. A DNA in isolated and purified form which encodes a platelet aggregation inhibitor (PAI) comprising naturally occurring protein amino acids, said PAI being capable of inhibiting binding of fibrinogen or von Willebrand Factor to GP IIb-IIIa with substantially more potency than of inhibiting binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which PAI comprises the amino acid sequence K*GDX, wherein X is an amino acid residue, and wherein K* is K.

10. A recombinant expression system capable, when transformed into a compatible host, of expressing a DNA encoding a specific platelet aggregation inhibitor (PAI) capable of inhibiting binding of Fg or vWF to GP IIb-IIIa with substantially more potency than of inhibiting binding of vitronectin to vitronectin receptor or fibronectin to fibronectin receptor, which PAI comprises the amino acid sequence KGDX, wherein X is an amino acid residue.

11. A recombinant host transformed with the expression system of claim 10.

12. A method to produce a GP IIb-IIIa specific PAI which method comprises:

culturing the host of claim 11 under conditions effective to express the PAI-encoding DNA to produce PAI; and

recovering the PAI from the culture.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc